<DOC>
	<DOCNO>NCT00594854</DOCNO>
	<brief_summary>This randomize , double-blind , parallel-group , control , multi-center clinical trial 6 month duration design assess efficacy , tolerability safety PN400 versus diclofenac/misoprostol subject high risk develop NSAID-associated gastric ulcer . Approximately 100 site participate enroll total 200 subject ( 100 per arm ) . At least 20 % subject enrol age 65 year old .</brief_summary>
	<brief_title>Evaluating PN 400 ( VIMOVO ) Reducing Gastric Ulcers High Risk Subjects Compared Arthrotec</brief_title>
	<detailed_description>To determine incidence gastric ulcer follow administration PN 400 high risk population six month . Diclofenac/misoprostol use positive control . Secondary : - To determine incidence duodenal ulcer treatment PN 400 diclofenac/misoprostol high risk population - To evaluate degree upper gastrointestinal injury measure Lanza score ( 1991 ) treatment PN400 diclofenac/misoprostol high risk population - To compare gastrointestinal symptom subject treat PN 400 versus diclofenac/misoprostol measure score Gastrointestinal Symptoms Rating Scale ( GSRS ) instrument - To evaluate safety tolerability PN400 diclofenac/misoprostol high risk population</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Stomach Ulcer</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<mesh_term>Misoprostol</mesh_term>
	<mesh_term>Diclofenac</mesh_term>
	<mesh_term>Naproxen</mesh_term>
	<mesh_term>Arthrotec</mesh_term>
	<criteria>1 . Male nonpregnant female subject , 18 year old history osteoarthritis , rheumatoid arthritis , ankylose spondylitis medical condition expect require daily NSAID therapy least 6 month , document history ulcer relate serious upper gastrointestinal event bleeding , perforation obstruction 2 . Female subject eligible participation study : Nonchildbearing potential ( i.e. , physiologically incapable become pregnant ) ; Childbearing potential , negative pregnancy test screening , least one follow applies agree subject : Female sterilization sterilization male partner ; , Hormonal contraception oral route , implant , injectable , vaginal ring ; , Any intrauterine device ( IUD ) publish data show low expected failure rate le 1 % per year ; Double barrier method ( 2 physical barrier 1 physical barrier plus spermicide ) ; Any method publish data show low expected failure rate le 1 % per year 3 . Each subject must able understand comply study procedure require subject able willing provide write informed consent prior study procedure perform 1 . History hypersensitivity esomeprazole another protonpump inhibitor 2 . History allergic reaction intolerance NSAID ( include aspirin ) and/or history NSAIDinduced symptom asthma , rhinitis , and/or nasal polyp 3 . Positive test result H. pylorus screen 4 . Participation study investigational treatment 4 week screen 5 . Presence uncontrolled acute chronic medical illness , e.g . gastrointestinal disorder , hypertension , diabetes , thyroid disorder , depression and/or infection would endanger subject participate study 6 . Gastrointestinal disorder surgery lead impaired drug absorption 7 . Evidence uncontrolled , unstable cardio cerebrovascular disorder , investigator 's opinion would endanger subject participate study 8 . Schizophrenia bipolar disorder 9 . Use excluded concomitant medication ( see Section 9.2 ) 10 . A recent history ( past 3 month ) suggestive alcohol drug abuse dependence , include overuse/abuse narcotics management pain 11 . Serious blood coagulation disorder , include use systemic anticoagulant 12 . Screening endoscopy show &gt; 10 erosion gastric duodenal ulcer least 3 mm diameter depth 13 . Screening laboratory ALT AST value &gt; 2 time upper limit normal 14 . Estimated creatinine clearance &lt; 50 ml/min 15 . Other note specifically , screen laboratory value clinically significant investigator 's opinion would endanger subject participate study 16 . History malignancy , treat untreated , within past 5 year , exception successfully treat basal cell squamous cell carcinoma skin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>NSAID</keyword>
	<keyword>Gastric Ulcer</keyword>
	<keyword>High risk</keyword>
	<keyword>Arthrotec</keyword>
	<keyword>Vimovo</keyword>
</DOC>